Kaveri Pohlman
Stock Analyst at Clear Street
(4.31)
# 1,383
Out of 4,692 analysts
222
Total ratings
40.3%
Success rate
11.9%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kaveri Pohlman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LBRX LB Pharmaceuticals | Rated: Buy | $45 → $69 | $47.26 | +46.00% | 2 | Aug 21, 2026 | |
| CGEM Cullinan Therapeutics | Rated: Buy | $46 → $47 | $22.07 | +112.96% | 20 | Aug 14, 2026 | |
| PTGX Protagonist Therapeutics | Rated: Buy | $116 → $173 | $147.75 | +17.09% | 6 | Aug 6, 2026 | |
| ELVN Enliven Therapeutics | Rated: Buy | $55 → $68 | $57.89 | +17.46% | 3 | Aug 6, 2026 | |
| EQ Equillium | Maintained: Buy | $9 | $2.27 | +296.48% | 2 | Aug 3, 2026 | |
| EVMN Evommune | Maintained: Buy | $28 | $12.66 | +121.17% | 3 | Jul 16, 2026 | |
| MLTX MoonLake Immunotherapeutics | Maintained: Buy | $70 | $15.05 | +365.12% | 6 | Jun 22, 2026 | |
| SGMT Sagimet Biosciences | Maintained: Buy | $37 → $28 | $10.26 | +172.90% | 4 | May 13, 2026 | |
| TRVI Trevi Therapeutics | Maintained: Buy | $21 → $29 | $16.60 | +74.70% | 3 | May 7, 2026 | |
| MDGL Madrigal Pharmaceuticals | Maintained: Buy | $533 → $680 | $540.03 | +25.92% | 3 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $71 → $131 | $92.62 | +41.44% | 4 | Apr 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $12 | $1.95 | +515.38% | 2 | Mar 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $11 → $20 | $17.88 | +11.86% | 3 | Mar 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $200 → $220 | $152.59 | +44.18% | 3 | Mar 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $32 → $12 | $18.22 | -34.14% | 4 | Jan 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $18 | $9.53 | +88.88% | 1 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $61 → $99 | $45.91 | +115.64% | 2 | Dec 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $25 | $21.36 | +17.04% | 2 | Dec 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $18 | $5.54 | +224.91% | 2 | Dec 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $12 | $6.66 | +80.18% | 17 | Nov 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $32 → $47 | $30.05 | +56.41% | 2 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $54.64 | n/a | 8 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $3.99 | n/a | 16 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $27.27 | n/a | 13 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $29.28 | n/a | 30 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $33.16 | n/a | 18 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $15.30 | n/a | 13 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $7.01 | n/a | 16 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $3.24 | n/a | 4 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $21 | $2.30 | n/a | 1 | Apr 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $0.00001 | n/a | 6 | Nov 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $16 → $8 | $3.36 | n/a | 3 | Jul 6, 2022 |
LB Pharmaceuticals
Aug 21, 2026
Rated: Buy
Price Target: $45 → $69
Current: $47.26
Upside: +46.00%
Cullinan Therapeutics
Aug 14, 2026
Rated: Buy
Price Target: $46 → $47
Current: $22.07
Upside: +112.96%
Protagonist Therapeutics
Aug 6, 2026
Rated: Buy
Price Target: $116 → $173
Current: $147.75
Upside: +17.09%
Enliven Therapeutics
Aug 6, 2026
Rated: Buy
Price Target: $55 → $68
Current: $57.89
Upside: +17.46%
Equillium
Aug 3, 2026
Maintained: Buy
Price Target: $9
Current: $2.27
Upside: +296.48%
Evommune
Jul 16, 2026
Maintained: Buy
Price Target: $28
Current: $12.66
Upside: +121.17%
MoonLake Immunotherapeutics
Jun 22, 2026
Maintained: Buy
Price Target: $70
Current: $15.05
Upside: +365.12%
Sagimet Biosciences
May 13, 2026
Maintained: Buy
Price Target: $37 → $28
Current: $10.26
Upside: +172.90%
Trevi Therapeutics
May 7, 2026
Maintained: Buy
Price Target: $21 → $29
Current: $16.60
Upside: +74.70%
Madrigal Pharmaceuticals
May 6, 2026
Maintained: Buy
Price Target: $533 → $680
Current: $540.03
Upside: +25.92%
Apr 27, 2026
Maintained: Buy
Price Target: $71 → $131
Current: $92.62
Upside: +41.44%
Mar 31, 2026
Maintained: Buy
Price Target: $12
Current: $1.95
Upside: +515.38%
Mar 6, 2026
Rated: Buy
Price Target: $11 → $20
Current: $17.88
Upside: +11.86%
Mar 2, 2026
Maintained: Buy
Price Target: $200 → $220
Current: $152.59
Upside: +44.18%
Jan 20, 2026
Downgraded: Hold
Price Target: $32 → $12
Current: $18.22
Upside: -34.14%
Dec 11, 2025
Reiterated: Buy
Price Target: $18
Current: $9.53
Upside: +88.88%
Dec 9, 2025
Maintained: Buy
Price Target: $61 → $99
Current: $45.91
Upside: +115.64%
Dec 1, 2025
Maintained: Buy
Price Target: $25
Current: $21.36
Upside: +17.04%
Dec 1, 2025
Maintained: Buy
Price Target: $18
Current: $5.54
Upside: +224.91%
Nov 26, 2025
Maintained: Buy
Price Target: $12
Current: $6.66
Upside: +80.18%
Nov 11, 2025
Maintained: Buy
Price Target: $32 → $47
Current: $30.05
Upside: +56.41%
Nov 29, 2024
Rated: Hold
Price Target: n/a
Current: $54.64
Upside: n/a
Nov 29, 2024
Rated: Hold
Price Target: n/a
Current: $3.99
Upside: n/a
Nov 29, 2024
Rated: Hold
Price Target: n/a
Current: $27.27
Upside: n/a
Nov 29, 2024
Rated: Hold
Price Target: n/a
Current: $29.28
Upside: n/a
Nov 29, 2024
Rated: Hold
Price Target: n/a
Current: $33.16
Upside: n/a
Nov 29, 2024
Rated: Hold
Price Target: n/a
Current: $15.30
Upside: n/a
Nov 29, 2024
Rated: Hold
Price Target: n/a
Current: $7.01
Upside: n/a
Nov 29, 2024
Rated: Hold
Price Target: n/a
Current: $3.24
Upside: n/a
Apr 29, 2024
Maintained: Buy
Price Target: $21
Current: $2.30
Upside: n/a
Nov 23, 2022
Downgraded: Hold
Price Target: n/a
Current: $0.00001
Upside: n/a
Jul 6, 2022
Rated: Buy
Price Target: $16 → $8
Current: $3.36
Upside: n/a